A role for oncostatin M in inflammatory bowel disease

被引：23
|
作者：
Kim, Walter M. [1 ]
Kaser, Arthur [2 ]
Blumberg, Richard S. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA
[2] Univ Cambridge, Dept Med, Div Gastroenterol & Hepatol, Cambridge, England
来源：
NATURE MEDICINE | 2017年 / 23卷 / 05期
关键词：
MAINTENANCE THERAPY; ULCERATIVE-COLITIS; CROHNS-DISEASE; INDUCTION; VEDOLIZUMAB;
D O I：
10.1038/nm.4338
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A new study identifies oncostatin M (OSM) as a potential biomarker and therapeutic target for anti-tumor necrosis factor (TNF)-refractory inflammatory bowel disease (IBD), and pinpoints mucosal stromal cells as key players in OSM-mediated inflammation.
引用
收藏
页码：535 / 536
页数：2
相关论文
共 50 条
  • [1] A role for oncostatin M in inflammatory bowel disease
    Walter M Kim
    Arthur Kaser
    Richard S Blumberg
    Nature Medicine, 2017, 23 : 535 - 536
  • [2] Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
    Yang, Yue
    Fu, Kan-Zuo
    Pan, Gu
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 16 (01):
  • [3] Oncostatin M and its receptor are markers of endoscopic and histological disease activity in Inflammatory Bowel Disease
    Nguyen, A.
    Sturm, G.
    Plattner, C.
    Trajanoski, Z.
    Atreya, R.
    Siegmund, B.
    Hegazy, A. N.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I397 - I398
  • [4] Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
    Verstockt, Sare
    Verstockt, Bram
    Machiels, Kathleen
    Vancamelbeke, Maaike
    Ferrante, Marc
    Cleynen, Isabelle
    De Hertogh, Gert
    Vermeire, Severine
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (10) : 1564 - 1575
  • [5] Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
    Verstockt, Sare
    Verstockt, Bram
    Vermeire, Severine
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (11) : 943 - 954
  • [6] Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort
    Ladipo, Jennifer Ezirike
    He, Zhaoping
    Chikwava, Kudakwashe
    Robbins, Katherine
    Beri, Jonathan
    Molle-Rios, Zarela
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 73 (03): : 352 - 357
  • [7] Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay
    Cao, Ying
    Dai, Yibei
    Zhang, Lingyu
    Wang, Danhua
    Yu, Qiao
    Hu, Wen
    Wang, Xuchu
    Yu, Pan
    Ping, Ying
    Sun, Tao
    Sang, Yiwen
    Liu, Zhenping
    Chen, Yan
    Tao, Zhihua
    CLINICAL BIOCHEMISTRY, 2022, 100 : 35 - 41
  • [8] Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
    Cao, Ying
    Dai, Yibei
    Zhang, Lingyu
    Wang, Danhua
    Hu, Wen
    Yu, Qiao
    Wang, Xuchu
    Yu, Pan
    Liu, Weiwei
    Ping, Ying
    Sun, Tao
    Sang, Yiwen
    Liu, Zhenping
    Chen, Yan
    Tao, Zhihua
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 6409 - 6419
  • [9] High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
    Angela Guo
    Cameron Ross
    Nilesh Chande
    Jamie Gregor
    Terry Ponich
    Reena Khanna
    Michael Sey
    Melanie Beaton
    Brian Yan
    Richard B. Kim
    Aze Wilson
    Scientific Reports, 12
  • [10] High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
    Guo, Angela
    Ross, Cameron
    Chande, Nilesh
    Gregor, Jamie
    Ponich, Terry
    Khanna, Reena
    Sey, Michael
    Beaton, Melanie
    Yan, Brian
    Kim, Richard B.
    Wilson, Aze
    SCIENTIFIC REPORTS, 2022, 12 (01)
12345